1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

Patent has been approved in China

MAR

ProstaLund AB has received the positive news that a utility model application for their product CoreFlow Soft Stent has been approved in China.

A utility model patent is a form of simpler patent that can be maintained for 10 years, in this case until 2033.

CoreFlow® Soft Stent is a multifunctional product that can replace or supplement a urodynamic examination and also be used when urodynamics alone is not applicable, for example if the patient cannot urinate or uses a catheter. The product can also be used while waiting for an active treatment.

"This approval is important in our efforts to strengthen IP protection around our stand-alone products and their future uses. Urodynamics is usually a bottleneck in healthcare with long waiting times of several months. With our product, the doctor can get answers to some of their questions within 30 minutes", says CEO Johan Wennerholm in a comment.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-08-15 12:00 CEST.

Attachments

Patent has been approved in China

Datum 2023-08-15, kl 12:00
Källa MFN
Bifogade filer
Patent has been approved in China
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!